BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29956721)

  • 21. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
    Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
    Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
    Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers.
    Rowland TJ; Bonham AJ; Cech TR
    Mol Oncol; 2020 Oct; 14(10):2358-2374. PubMed ID: 33245585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
    Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter mutations in clear cell renal cell carcinoma.
    Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
    Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
    Gertler R; Rosenberg R; Stricker D; Friederichs J; Hoos A; Werner M; Ulm K; Holzmann B; Nekarda H; Siewert JR
    J Clin Oncol; 2004 May; 22(10):1807-14. PubMed ID: 15143073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant methylation of the TERT promoter in esophageal squamous cell carcinoma.
    Deng J; Zhou D; Zhang J; Chen Y; Wang C; Liu Y; Zhao K
    Cancer Genet; 2015 Dec; 208(12):602-9. PubMed ID: 26669682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
    Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
    Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.
    Widschwendter A; Müller HM; Hubalek MM; Wiedemair A; Fiegl H; Goebel G; Mueller-Holzner E; Marth C; Widschwendter M
    Gynecol Oncol; 2004 May; 93(2):407-16. PubMed ID: 15099954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
    Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
    Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
    Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.
    Hofland J; Steenbergen J; Voorsluijs JM; Verbiest MM; de Krijger RR; Hofland LJ; de Herder WW; Uitterlinden AG; Feelders RA; de Jong FH
    PLoS One; 2014; 9(8):e104944. PubMed ID: 25111790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.
    Huang W; Zhou W; Li C; Yang Y; Shang YK; Chen C; Zhang J; Yao R; Wang P; Wen W; Liu HQ; Wang L; Li X; Bian H; Chen ZN
    Oncotarget; 2017 Apr; 8(16):26288-26297. PubMed ID: 28460432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.
    Miyake Y; Adachi JI; Suzuki T; Mishima K; Araki R; Mizuno R; Nishikawa R
    J Neurooncol; 2019 Jan; 141(1):131-138. PubMed ID: 30392088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
    Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
    Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
    Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
    Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.